Cathie Wood's Ark Invest has loaded up on these 2 small-cap names for the last 7 trading sessionsBusiness Insider • 02/08/23
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Repare Therapeutics Inc. (RPTX) InvestigationBusiness Wire • 02/08/23
Repare Therapeutics Inc. (RPTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 01/20/23
Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono PharmaceuticalsBusiness Wire • 01/19/23
Repare Therapeutics Inc. (RPTX) Just Overtook the 20-Day Moving AverageZacks Investment Research • 12/02/22
How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 95%Zacks Investment Research • 12/01/22
Can Repare Therapeutics Inc. (RPTX) Climb 106% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 11/14/22
Repare Therapeutics Inc. (RPTX) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 11/09/22
Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial ResultsBusiness Wire • 11/09/22
Repare Therapeutics: Budding Synthetic Lethality Player With 3 Big Pharma PartnersSeeking Alpha • 09/07/22
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial ResultsBusiness Wire • 08/04/22
Repare Therapeutics stock is down as insiders flock to buy the $30-million RPTX dipFinbold • 06/13/22
Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare ConferenceBusiness Wire • 06/07/22
Repare Therapeutics shares rise by 25% after it announced its collaboration deal with RocheInvezz • 06/04/22
Roche, Repare's licensing deal includes milestone payments worth up to $1.2 billionMarket Watch • 06/02/22
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)Business Wire • 06/01/22
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality DayBusiness Wire • 05/09/22
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial ResultsBusiness Wire • 05/05/22
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 AmplificationBusiness Wire • 04/20/22
Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar?Zacks Investment Research • 04/13/22